These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 24125420)

  • 21. Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD.
    Di Marco GS; Reuter S; Kentrup D; Grabner A; Amaral AP; Fobker M; Stypmann J; Pavenstädt H; Wolf M; Faul C; Brand M
    Nephrol Dial Transplant; 2014 Nov; 29(11):2028-35. PubMed ID: 24875663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Longitudinal association of body mass index and waist circumference with left ventricular mass in hypertensive predialysis chronic kidney disease patients.
    Stel VS; Ioannou K; Brück K; Dounousi E; Pappas K; Siamopoulos KC; Zoccali C; Jager KJ; Tsakiris D
    Nephrol Dial Transplant; 2013 Nov; 28 Suppl 4(Suppl 4):iv136-45. PubMed ID: 24049104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vitamin D treatment attenuates cardiac FGF23/FGFR4 signaling and hypertrophy in uremic rats.
    Leifheit-Nestler M; Grabner A; Hermann L; Richter B; Schmitz K; Fischer DC; Yanucil C; Faul C; Haffner D
    Nephrol Dial Transplant; 2017 Sep; 32(9):1493-1503. PubMed ID: 28339837
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients.
    Hsu HJ; Wu MS
    Am J Med Sci; 2009 Feb; 337(2):116-22. PubMed ID: 19214027
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between circulating fibroblast growth factor 23, α-Klotho, and the left ventricular ejection fraction and left ventricular mass in cardiology inpatients.
    Shibata K; Fujita S; Morita H; Okamoto Y; Sohmiya K; Hoshiga M; Ishizaka N
    PLoS One; 2013; 8(9):e73184. PubMed ID: 24039882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Four-group classification of left ventricular hypertrophy based on ventricular concentricity and dilatation identifies a low-risk subset of eccentric hypertrophy in hypertensive patients.
    Bang CN; Gerdts E; Aurigemma GP; Boman K; de Simone G; Dahlöf B; Køber L; Wachtell K; Devereux RB
    Circ Cardiovasc Imaging; 2014 May; 7(3):422-9. PubMed ID: 24723582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FGF23-Mediated Activation of Local RAAS Promotes Cardiac Hypertrophy and Fibrosis.
    Böckmann I; Lischka J; Richter B; Deppe J; Rahn A; Fischer DC; Heineke J; Haffner D; Leifheit-Nestler M
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540546
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fibroblast Growth Factor 23 and the Risk of Infection-Related Hospitalization in Older Adults.
    Nowak KL; Bartz TM; Dalrymple L; de Boer IH; Kestenbaum B; Shlipak MG; Garimella PS; Ix JH; Chonchol M
    J Am Soc Nephrol; 2017 Apr; 28(4):1239-1246. PubMed ID: 28122946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FGF23/FGFR4-mediated left ventricular hypertrophy is reversible.
    Grabner A; Schramm K; Silswal N; Hendrix M; Yanucil C; Czaya B; Singh S; Wolf M; Hermann S; Stypmann J; Di Marco GS; Brand M; Wacker MJ; Faul C
    Sci Rep; 2017 May; 7(1):1993. PubMed ID: 28512310
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Markers of kidney disease and risk of subclinical and clinical heart failure in African Americans: the Jackson Heart Study.
    Bansal N; Katz R; Himmelfarb J; Afkarian M; Kestenbaum B; de Boer IH; Young B
    Nephrol Dial Transplant; 2016 Dec; 31(12):2057-2064. PubMed ID: 27257276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FGF23 in hemodialysis patients is associated with left ventricular hypertrophy and reduced ejection fraction.
    Nielsen TL; Plesner LL; Warming PE; Mortensen OH; Iversen KK; Heaf JG
    Nefrologia (Engl Ed); 2019; 39(3):258-268. PubMed ID: 30723045
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PTH, FGF23, and Intensive Blood Pressure Lowering in Chronic Kidney Disease Participants in SPRINT.
    Ginsberg C; Craven TE; Chonchol MB; Cheung AK; Sarnak MJ; Ambrosius WT; Killeen AA; Raphael KL; Bhatt UY; Chen J; Chertow GM; Freedman BI; Oparil S; Papademetriou V; Wall BM; Wright CB; Ix JH; Shlipak MG;
    Clin J Am Soc Nephrol; 2018 Dec; 13(12):1816-1824. PubMed ID: 30425104
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Left Ventricular Mass and Incident Chronic Kidney Disease.
    Agarwal R; Song RJ; Vasan RS; Xanthakis V
    Hypertension; 2020 Mar; 75(3):702-706. PubMed ID: 31928112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease: findings from the CKD-JAC study.
    Nitta K; Iimuro S; Imai E; Matsuo S; Makino H; Akizawa T; Watanabe T; Ohashi Y; Hishida A
    Clin Exp Nephrol; 2019 Jan; 23(1):85-98. PubMed ID: 29951723
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Associations of Left Ventricular Hypertrophy and Geometry with Adverse Outcomes in Patients with CKD and Hypertension.
    Paoletti E; De Nicola L; Gabbai FB; Chiodini P; Ravera M; Pieracci L; Marre S; Cassottana P; Lucà S; Vettoretti S; Borrelli S; Conte G; Minutolo R
    Clin J Am Soc Nephrol; 2016 Feb; 11(2):271-9. PubMed ID: 26668021
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The FGF23-Klotho axis and cardiac tissue Doppler imaging in pediatric chronic kidney disease-a prospective cohort study.
    Tranæus Lindblad Y; Olauson H; Vavilis G; Hammar U; Herthelius M; Axelsson J; Bárány P
    Pediatr Nephrol; 2018 Jan; 33(1):147-157. PubMed ID: 28795324
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Indexation of left ventricular mass to predict adverse clinical outcomes in pre-dialysis patients with chronic kidney disease: KoreaN cohort study of the outcome in patients with chronic kidney disease.
    Lee SW; Min HK; Chae DW; Oh KH; Ahn C; Chung W; Lee J; Kim YS; Sung SA;
    PLoS One; 2020; 15(5):e0233310. PubMed ID: 32428014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of fibroblast growth factor-23 in cardiorenal syndrome.
    Kovesdy CP; Quarles LD
    Nephron Clin Pract; 2013; 123(3-4):194-201. PubMed ID: 23942553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Associations of fibroblast growth factor 23, vitamin D and parathyroid hormone with 5-year outcomes in a prospective primary care cohort of people with chronic kidney disease stage 3.
    Shardlow A; McIntyre NJ; Fluck RJ; McIntyre CW; Taal MW
    BMJ Open; 2017 Aug; 7(8):e016528. PubMed ID: 28838895
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy.
    Grabner A; Amaral AP; Schramm K; Singh S; Sloan A; Yanucil C; Li J; Shehadeh LA; Hare JM; David V; Martin A; Fornoni A; Di Marco GS; Kentrup D; Reuter S; Mayer AB; Pavenstädt H; Stypmann J; Kuhn C; Hille S; Frey N; Leifheit-Nestler M; Richter B; Haffner D; Abraham R; Bange J; Sperl B; Ullrich A; Brand M; Wolf M; Faul C
    Cell Metab; 2015 Dec; 22(6):1020-32. PubMed ID: 26437603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.